AzTrials
AzTrials

InfertilityPANDORANCT06524648

International Pilot Study for Dual Non-invasive Assesment of Embryo Development

An observational study of Infertility, run by Igenomix at 8 sites in 3 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Choosing the best embryo is one of the major challenges for achieving success in in vitro fertilization (IVF). Traditionally, embryo evaluation has been based on morphological quality (how the embryo looks like) and chromosomal status as diagnosed by a genetic testing. Read more about this study

Who is it for?
Ages 20 to 42 years, women only
Conditions the study is for
Infertility
What is being tested?
niPGT-A
How many people
200 participants
Where
8 sitesin 3 countries
Study dates
29 Oct 2024to Jul 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 42 years
  • Women only
  • No healthy volunteers
  • Adult

Study population: Infertile women complying with the selection criteria who are patients at an assisted reproduction center and, by medical recommendation, are undergoing a fertility treatment with non-invasive preimplantational genetic testing for aneuploidies.

Who may be able to join

  • Study ICF signature.
  • Female age between 20 and 42 years (bot included).
  • IVF, ICSI or IVF/ICSI performed in fresh own or donated oocytes. Note: donor sperm is allowed.
  • niPGT-A cases with a deferred SET (of a day 6/7 vitrified blastocyst) for any medical indication.
  • Embryos cultured individually in a TL system from day 0/1 to day 6/7.

Who cannot join

  • Embryos with abnormal fertilization (different from 2PN). (Note: In case of no 2PN embryos, patients may repeat the COS cycle).
  • Female/couple with PGT-M and/or PGT-SR indication.
  • Assisted hatching and/or artificial collapse before media collection.
  • Known abnormal karyotype.
  • Pathologies or malformations affecting the uterine cavity (polyps, intramural myomas ≥ 4cm or submucosal, septum or hydrosalpinx) during the patient's participation. (Note: patients are allowed to participate if the pathology is previously operated at least 3 months before patient enrollment).
  • Any illness or medical condition that is unstable or which, according to medical criteria, may put at risk the patient's safety and her compliance in the study.

Trial locations and contacts

8 sites in 3 countries. Contact the study team or a site near you to ask about taking part.

Carlos Gomez, BSc MSc contact

+34963905310

carlos.gomez@igenomix.com

Ianae Ceschin, MSc contact

embrace@igenomix.com

8 sites in 3 countries

Spain6 sites, 6 recruiting
  • Fertty

    Barcelona, Barcelona, 08010

    Mariona Rius, +34 937378190, mariona.rius@fertty.com

    Recruiting
  • Hospital Ruber Internacional

    Madrid, Madrid, 28034

    Jesus Maria R Franco, +34913875000, jesusm.franco@ruberinternacional.es

    Recruiting
  • Next Fertility Murcia

    Murcia, Murcia, 30007

    Paloma Piqueras, +34 968 90 19 03, paloma.piqueras@next-clinics.com

    Emilio Gomez, emilio.gomez@nextfertility.es

    Recruiting
  • Next Fertility Sevilla

    Seville, Sevilla, 41012

    Paloma Piqueras, +34 954 45 61 69, paloma.piqueras@next-clinics.com

    Rocio Diaz, rocio.diaz@nextfertility.es

    Recruiting
  • Vida Recoletas Sevilla

    Seville, 41092

    Manuel Fernandez, MD, +34 954286274, manuel.fernandez@gruporecoletas.com

    Nicolas Prados, nicolas.prados@gruporecoletas.com

    Recruiting
  • Next Fertility Valencia

    Valencia, Valencia, 46009

    Paloma Piqueras, +34 963 16 02 40, paloma.piqueras@next-clinics.com

    Vicente Llosa, vicente.llosa@nextfertility.es

    Recruiting

Other trials in Spain

Austria1 site, 1 recruiting
  • Kinderwunsch Institut Schenk

    Dobl, A-8143

    Michael Schenk, MD, +43 (0) 3136 55 111, Michael.Schenk@kinderwunsch-institut.at

    Recruiting

Other trials in Austria

United Arab Emirates1 site, 1 recruiting
  • Orchid IVF Clinic

    Dubai

    Maria Banti, +971 4 427 2852, maria.b@orchid-fertility.com

    Recruiting

Other trials in United Arab Emirates

About this study

Official title: A Prospective, Multicenter, Observational Pilot Study to Evaluate the Combination of niPGT-A and Morphokinetics for the Non-invasive Assessment of Embryo Development

Choosing the best embryo is one of the major challenges for achieving success in in vitro fertilization (IVF). Traditionally, embryo evaluation has been based on morphological quality (how the embryo looks like) and chromosomal status as diagnosed by a genetic testing. However, recently new techniques that do not require manipulation of the embryo have been developed and have shown promising results.

The goal of this observational study is, by combining two non-invasive techniques, to find out some parameters during embryo development which may be related with the embryo's chromosomic status. For that, infertile women planning to undergo an IVF/ICSI treatment with a recommended niPGT-A (non-invasive Preimplantation Genetic Testing for Aneuploidies) will be invited to join the study. The main question it aims to answer is:

Read more
  • Can morphokinetics parameters correlate with embryo chromosomal status?

Participants will follow their previously programmed IVF/ICSI treatment and no additional visits/interventions will be required by their participation in the study. The obtained embryos will be cultured in a time-lapse system instead of in a conventional incubator, and niPGT-A will be performed. Following the standard practice, a deferred single embryo transfer (SET) will be performed according to the niPGT-A results. After the transfer, patients will be followed-up as usual.

Read the detailed description

Embryo selection represents one of the major challenges for achieving success in in vitro fertilization (IVF) cycles. Traditionally, embryo evaluation has been based on morphological quality and chromosomal status as diagnosed by a genetic testing. However, recently new non-invasive techniques that do not require additional manipulation of the embryo have been developed and have shown promising results. One such technique is the time-lapse (TL) system imaging, which considers the embryo's development in relation to its rate of division and evolution (morphokinetics). Several algorithms have been developed to aid in the selection of embryos with the highest potential for implantation by collecting data on morphokinetic events during in vitro preimplantation development. Another non-invasive method is the analysis of the cell-free desoxyribonucleic acid (cfDNA) in the culture medium, considered as a non-invasive preimplantation genetic testing for aneuploidies (niPGT-A). Despite both techniques have shown promising results, each one has its limitations, and further research is necessary to identify synergies between them with the aim of finding a more powerful approach for embryo viability evaluation.

The combination of TL and niPGT-A might have the potential to improve the embryo evaluation and thus to improve the reproductive outcome rates in IVF treatments. Therefore, the aim of the present pilot study is to identify morphokinetic parameters during embryo development in a time-lapse system which may correlate with niPGT-A results.

Once the study is approved by the competent Research Ethics Committee of each center, the recruitment and selection of patients will follow. Every potential participant will be asked to sign the study informed consent. To comply with the study design and the proposed hypothesis, an estimated total number of 200 patients will be recruited.

This is a multicenter, international, competitive, observational, prospective cohort study in which infertile women scheduled for an IVF/ICSI treatment with medical recommendation of niPGT-A will have their embryos cultured in a time-lapse system instead of in a standard incubator. On day 6/7 of embryo development, the embryo's culture medium will be collected and analyzed by niPGT-A. A subsequent embryo transfer will be performed following the niPGT-A report recommendation and participants will be followed up as routine by their gynecologist. If a pregnancy is achieved, participants will be followed up until the 12th gestational week and, if possible, until the delivery. If pregnancy is not achieved, patients can perform as many SET/COS as they need during the study recruitment period.

Data exported from the medical records and source documents will be duly codified to protect the clinical and personal information of patients in accordance with the current legislation on data protection. This information will be exported to an internal database. An interim data analysis will be carried out once the 50% of the niPGT-A cycles (100 cycles) is reached. It will help us to assess the enrollment rate, protocol compliance and an early evaluation of the study objectives.

Patient´s participation will comprise an estimated total time of up to 11 months: 1 month for the COS cycle + 1 month for the ET cycle + ≤ 9 months for the follow-up period (≤12th gestational week and ≤ 40th gestational week, when applicable).

Conditions
Infertility
Being tested
niPGT-A
Keywords
Infertility, In vitro fertilization, Time lapse, niPGT-A, Embryo Development, Embryonic cell-free DNA, Morphokinetics, Artificial Intelligence, Embryo selection, Blastocyst, Ongoing pregnancy rate
Medical subject headings
Infertility

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • niPGT-ADiagnostic test

    Embryos will be cultured, from oocyte fertilization up to day 6/7 of development, in a time lapse system following the standard practice. On day 6/7, embryos will be vitrified and the embryos's media will be collected for niPGT-A analysis.

    Patients will undergo a single embryo transfer (SET) following the niPGT-A report indications. In the event of 1 or more embryos with the same niPGT-A score, the embryo for transfer will be determined by the site standard practice (morphology or time-lapse score).

    Patients who do not achieve a pregnancy after a niPGT-A guided SET can undergo as many niPGT-A guided SET or COS+niPGT-A cycles as they need to get pregnant, while the study recruitment phase is active.

Study groups in NCT06524648
Study groupRoleWhat they receive
Infertile women with medical recommendation of niPGT-APatients will not undergo any additional intervention apart from those already scheduled for their ART. The only study specific procedures are the culture of the embryos in a timelapse system and the collection of the embryo's culture media, which is usually discarded. Both procedures will be performed following the stardard practice. No drugs will be administered as per the study.
Receives: Diagnostic Test: niPGT-A

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Identification of embryo morphokinetic parameters which correlate with niPGT-A results

    Comparison of embryo morphokinetic parameters from the time-lapse (day 0 to day 6/7) with the niPGT-A results (informativity and ploidy)

    Measured: Up to 6/7 days

Secondary outcomes (12)
  1. Correlation between the implantation rate (IR) and embryo morphokinetic parameters in the niPGT-A guided single embryo transfer (SET)

    Analysis to determine the correlation between morphokinetic parameters and the IR, defined as the number of gestational sacs observed by vaginal ultrasound divided by the number of embryos transferred.

    Measured: Up to 4 weeks after the embryo transfer

  2. Correlation between the clinical pregnancy rate (CPR) and embryo morphokinetic parameters in the niPGT-A guided single embryo transfer (SET)

    Analysis to determine the correlation between morphokinetic parameters and the CPR, defined as the number of pregnancies with ultrasonographic visualization of one or more gestational sacs and/or fetal heartbeat, per embryo transfer.

    Measured: Up to 5-6 weeks after the embryo transfer

  3. Correlation between the biochemical pregnancy rate (BPR) and embryo morphokinetic parameters in the niPGT-A guided single embryo transfer (SET)

    Analysis to determine the correlation between morphokinetic parameters and the BPR, defined as the number of pregnancies diagnosed only by β-hCG detection (≥25 mIU/ml) without a gestational sac visualized by vaginal ultrasound, per number of pregnancies.

    Measured: Around 2 weeks after the embryo transfer

  4. Correlation between the ectopic pregnancy rate (EPR) and embryo morphokinetic parameters in the niPGT-A guided single embryo transfer (SET)

    Analysis to determine the correlation between morphokinetic parameters and EPR, defined as the number of pregnancies outside the uterine cavity, diagnosed clinically, hormonally, by ultrasound, surgical visualization or histopathology, per number of pregnancies.

    Measured: Up to 4-5 weeks after the embryo transfer

  5. Correlation between the clinical miscarriage rate (CMR) and embryo morphokinetic parameters in the niPGT-A guided single embryo transfer (SET)

    Analysis to determine the correlation between morphokinetic parameters and the CMR, defined as the number of spontaneous pregnancy losses before the 12th gestational week, in which a gestational sac/s was previously observed and heartbeat detected, per number of pregnancies.

    Measured: Over 12 gestational weeks

  6. Correlation between the ongoing pregnancy rate (OPR) and embryo morphokinetic parameters in the niPGT-A guided single embryo transfer (SET)

    Analysis to determine the correlation between morphokinetic parameters and the OPR, defined as the number of pregnancies of, at least,12 gestational weeks (at least one fetus with a discernible heartbeat diagnosed) achieved per each embryo transfer.

    Measured: ≥12 gestational weeks

  7. Correlation between the Live Birth Rate (LBR) and embryo morphokinetic parameters in the niPGT-A guided single embryo transfer (SET)

    Analysis to determine the correlation between morphokinetic parameters and the LBR, defined as the number of live births per embryo transfer. Live birth is defined as the complete expulsion or extraction from a woman of a product of conception after 22 weeks of gestation, which, after such separation, breathes or shows any other evidence of life, such as heartbeat, umbilical cord pulsation or definite movement of voluntary muscles, irrespective of whether the umbilical cord has been cut or the placenta is attached.

    Measured: 40 gestational weeks

  8. Identification of morphokinetic parameters which might predict the optimal time for media collection.

    Comparison of niPGT-A informativity results with morphokinetic parameters

    Measured: Up to 6/7 days of embryo development

  9. To explore the relationship between niPGT-A results and morphokinetics with the type of ovarian stimulation and induction, the patient's intertility history and embryo quality

    Multivariant analysis to determine how the relationship between niPGT-A results and morphokinetics is affected by ART/patient variables: type of ovarian stimulation and induction, the patient's intertility history (previous miscarriages, known infertility causes, previous implantation failures), and embryo quality (determined by standard morphology evaluation).

    Measured: Over 3-4 weeks

  10. Identification of the correlation between morphokinetic parameters and spent blastocyst media contamination

    Correlate morphokinetic parameters with the presence of maternal and/or external DNA in the culture media for niPGT-A

    Measured: Up to 6/7 days of embryo development

  11. Comparison of the products of conception (POC) results with the niPGT-A results

    Correlate the niPGT-A results with the POC results

    Measured: Up to 12 gestational weeks

  12. To study the relathionship among the morphokinetics, niPGT-A and the patient's body mass index (BMI)

    To anlyse the patient's BMI influence on the correlation between morphokinetics and niPGT-A, only when own oocytes are used.

    Measured: Up to 6/7 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jul 2024
  2. Study start29 Oct 2024
  3. Primary completionJul 2027 (estimated)
  4. Study completionJul 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06524648
Sponsor's protocol ID
IGX1-EES-CR-23-01
Acronym
PANDORA
Status last verified
Nov 2026
First submitted
23 Jul 2024
Last updated
6 Nov 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Infertility, run by Igenomix at 8 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in Spain, Austria, United Arab Emirates. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Carlos Gomez, BSc MSc (+34963905310, carlos.gomez@igenomix.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Identification of embryo morphokinetic parameters which correlate with niPGT-A results (time frame: Up to 6/7 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in